About
Technology
Issues
FAQ
Search
filter by year
2024 (3)
2023 (105)
2022 (328)
2021 (408)
2020 (386)
2010-2019 (2,946)
2000-2009 (1,807)
1990-1999 (1,198)
1980-1989 (768)
1970-1979 (428)
1960-1969 (254)
1950-1959 (165)
1900-1950 (142)
Similar Keywords
clinical investigation (9,046)
41-60 of (9,046 documents found)
2019
461
Heart Failure With Preserved Ejection Fraction In Perspective
Circulation Research
(
4.5
★★★
), 124, 1598-1617.
Cite
Citations
Matthew Li (80, 6.9K)
2020
381
The Therapeutic Potential of Nanobodies
BioDrugs
(
4.6
★★★
), 34, 11-26.
Cite
Citations
Matthew Li (80, 6.9K)
2015
486
Lung cancer: Biology and treatment options
Biochimica Et Biophysica Acta: Reviews on Cancer
(
7.4
★★★
), 1856, 189-210.
Cite
Citations
Matthew Li (80, 6.9K)
2014
720
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics
(
4.1
★★★
), 13, 890-901.
Cite
Citations
Matthew Li (80, 6.9K)
2012
756
RNA-Based Therapeutics: Current Progress and Future Prospects
Chemistry and Biology
(
6.0
★★★
), 19, 60-71.
Cite
Citations
Matthew Li (80, 6.9K)
2022
64
Signaling pathways of chronic kidney diseases, implications for therapeutics
Signal Transduction and Targeted Therapy
(
17.1
★★★
), 7, .
Cite
Citations
Matthew Li (80, 6.9K)
2020
196
CAR T cells: continuation in a revolution of immunotherapy
Lancet Oncology, The
(
10.7
★★★
), 21, e168-e178.
Cite
Citations
Matthew Li (80, 6.9K)
2020
138
Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases
Advanced Drug Delivery Reviews
(
13.7
★★★
), 165-166, 15-40.
Cite
Citations
Matthew Li (80, 6.9K)
2019
170
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Nature Communications
(
12.8
★★★
), 10, 5065.
Cite
Citations
Matthew Li (80, 6.9K)
2012
516
Mycobacterium tuberculosis
: success through dormancy
FEMS Microbiology Reviews
(
8.6
★★★
), 36, 514-532.
Cite
Citations
Matthew Li (80, 6.9K)
2020
119
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Immunity
(
14.3
★★★
), 52, 36-54.
Cite
Citations
Matthew Li (80, 6.9K)
2018
300
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
Cell Reports
(
6.4
★★★
), 22, 2978-2994.
Cite
Citations
Matthew Li (80, 6.9K)
2018
146
Options and Limitations in Clinical Investigation of Bacterial Biofilms
Clinical Microbiology Reviews
(
13.6
★★★
), 31, .
Cite
Citations
Matthew Li (80, 6.9K)
2017
109
Emerging therapies for acute myeloid leukemia
Journal of Hematology and Oncology
(
17.0
★★★
), 10, 93.
Cite
Citations
Matthew Li (80, 6.9K)
2020
71
m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance
Signal Transduction and Targeted Therapy
(
17.1
★★★
), 5, 296.
Cite
Citations
Matthew Li (80, 6.9K)
2020
194
MDM2 inhibition: an important step forward in cancer therapy
Leukemia
(
7.2
★★★
), 34, 2858-2874.
Cite
Citations
Matthew Li (80, 6.9K)
2020
196
Emerging pharmaceutical therapies for osteoarthritis
Nature Reviews Rheumatology
(
8.0
★★★
), 16, 673-688.
Cite
Citations
Matthew Li (80, 6.9K)
2017
270
Isocitrate dehydrogenase mutations in myeloid malignancies
Leukemia
(
7.2
★★★
), 31, 272-281.
Cite
Citations
Matthew Li (80, 6.9K)
2017
285
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
(
6.1
★★★
), 9, e1416.
Cite
Citations
Matthew Li (80, 6.9K)
2015
258
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
Molecular Cell
(
9.7
★★★
), 58, 1028-1039.
Cite
Citations
Matthew Li (80, 6.9K)
1
2
3
4
5
site/software ©
exaly
; All materials licenced under
CC by-SA
.